1921
Volume 73, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

In this multicenter study in Lebanon, hepatitis A virus (HAV) seroprevalence rates were surveyed by age, gender, and socioeconomic factors. Blood samples collected from 606 subjects aged 1 to 30 years were analyzed for anti-HAV IgG. Age was the most important factor influencing HAV seroprevalence. HAV seroprevalence rates in the current study were about 78% in the ≥ 21 years age group, 28% in the 6–10 years age group, and 11% in the 1–5 years age group as compared with 97.7% in adults, 85% in children aged 6–12 years, and 40% in children aged 1 to 5 years in previous studies, demonstrating a shift in HAV seroprevalence from the younger to the higher age groups. In light of the severity of the disease in adults and availability of safe and effective vaccines against HAV infection, introduction of HAV vaccination into the national immunization schedule of Lebanon should be considered.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2005.73.453
2005-08-01
2017-09-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/73/2/0730453.html?itemId=/content/journals/10.4269/ajtmh.2005.73.453&mimeType=html&fmt=ahah

References

  1. WHO, 2000. Hepatitis A vaccines, WHO position paper. Wkly Epidemiol Rec 75 : 38–44.
  2. Battegay M, Gust ID, Feinstone SM, 1995. Hepatitis A virus. Mandell JL, Benett JE, eds. Principles and Practice of Infectious Disease. New York: Churchill Livingstone 1636–1656.
  3. Hadler SC, 1991. Global impact of hepatitis A virus infection changing patterns. Hollinger FB, Lemon SM, Margolis H, eds. Viral Hepatitis and Liver Disease. Baltimore: Williams & Wilkins, 14–20
  4. Gust ID, 1992. Epidemiological patterns of hepatitis A in different parts of the world. Vaccine 10 : S56–S58.
  5. Gay NJ, Morgan-Capner P, Wright J, Farrington CP, Miller E, 1994. Age-specific antibody prevalence to hepatitis A in England: implications for disease control. Epidemiol Infect 113 : 113–120.
  6. Werzbeger A, Mensch B, Kuter B, Brown L, Lewis J, Sitrin R, Miller W, Shouval D, Wiens B, Calandra G, 1992. A controlled trial of formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 327 : 453–457.
  7. Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA, Suntayakorn S, Suknuntapong T, Safary A, Tang DB, Boslego JW, 1994. Protection against hepatitis A by an inactivated vaccine. JAMA 271 : 1328–1334.
  8. Andre FE, D’Hondt E, Delem A, Safary A, 1992. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine 10 (Suppl 1): S160–S168.
  9. Andre F, Van Damme P, Safary A, Banatvala J, 2000. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Expert Rev Vaccines 1 : 9–23.
  10. Lebanese decree no 8733. Fixing the minimum wages of the employees and workers as well as the increase of the cost of living. Lebanese Official Gazette (in Arabic: Jaride Al Rasmiye) Lebanon, Published on 8 July 1996.
  11. Shammaa MH, Abu-Samra S, Salameh V, Nassar NT, 1982. The significance of anti-HAV in different population sectors in Lebanon: a comparative seroepidemiologic study. Int J Epidemiol 11 : 406–409.
  12. Kalaajieh W, Rima A, Dennaoui M, Al Khodayry R, 2000. Seroprevalence of hepatitis A antibodies in Lebanese children. Med Mal Infect 30 : 757–761.
  13. Tanaka J, 2000. Hepatitis A shifting epidemiology in Latin America. Vaccine 18 (Suppl 1): S57–S60.
  14. Poovorawan Y, Theamboonlers A, Sinlaparatsamee S, Chaiear K, Siraprapasiri T, Khwanjaipanich S, Owatanapanich S, Hirsch P, 2000. Increasing susceptibility to HAV among members of the young generation in Thailand. Asian Pac J Allergy Immunol 18 : 249–253.
  15. Tufenkeji H, 2000. Hepatitis A shifting epidemiology in the Middle East and Africa. Vaccine 18 (Suppl 1): S65–S67.
  16. Green MS, Aharonowitz G, Shohat T, Levine R, Anis E, Slater PE, 2001. The changing epidemiology of viral hepatitis A in Israel. Isr Med Assoc J 3 : 347–351.
  17. Halliday ML, Kang LY, Zhou TK, Hu MD, Pan QC, Fu TY, Huang YS, Hu SL, 1991. An epidemic of hepatitis A attributable to the ingestion of raw clams in Shanghai, China. J Infect Dis 164 : 852–859.
  18. WHO, 1995. Public health control of hepatitis A: memorandum from a WHO meeting. Bull WHO 73 : 15–20.
  19. McMahon BJ, Beller M, Williams J, Schloss M, Tanttila H, Bulkow L, 1996. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch Pediatr Adolesc Med 150 : 733–739.
  20. Salleras L, Bruguera M, Buti M, Domingez A, 2000. Prospects for vaccination against hepatitis A and B in Catalonia (Spain). Vaccine 18 (Suppl 1): S80–S82.
  21. Germinario C, Lopalco PL, Chicanna M, Da Villa G, 2000. From hepatitis B to hepatitis A and B prevention: the Puglia (Italy) experience. Vaccine 18 (Suppl 1): S83–S85.
  22. Fishman RH, 1998. Hepatitis A vaccine for Israeli children. Lancet 352 : 88846.
  23. Dominguez A, Salleras L, Carmona G, Batalla J, 2003. Effectiveness of a mass hepatitis A vaccination program in pre-adolescents. Vaccine 21 : 698–701.
  24. Demicheli V, Carniglia E, Fucci S, 2003. The use of hepatitis a vaccination in Italy: an economic evaluation. Vaccine 21 : 2250–2257.
  25. Ginsber GM, Slater PE, Shouval D, 2001. Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity. J Hepatol 34 : 92–99.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2005.73.453
Loading
/content/journals/10.4269/ajtmh.2005.73.453
Loading

Data & Media loading...

  • Received : 03 Aug 2004
  • Accepted : 02 Mar 2005

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error